Office of Technology Management

chnology ent O Te M m ffi of a e ic na g e e g a o ic n fi e a f f m T M e O e c y n h g t n o l o

a f c

e o

c f

a e O

y o

g l o

U I C

Office of Technology Management Fiscal Year 2007 Annual Report • University of Illinois at Chicago Office of Technology Management • University of Illinois at Chicago (MC 682)

1853 West Polk Street, Suite 446 • Chicago, Illinois 60612

From the Director 03 About the Office 04 Invention Disclosures 05 Licensing Activity 05 Patent Activity 06 Income Distribution 08 Income and Expenses 08 FDA-Approved Drug 09 Technologies 10 Contacts 14

Reporting Looking Ahead: Fiscal 2008 Goals The Office of Technology Management OTM( ) reports to Dr. A report on fiscal2007 activity would be incomplete without Avijit Ghosh, the Vice President for Technology and Economic looking ahead to fiscal 2008. Our focus in the coming year Development, and also works closely with the Interim Vice will be on the following areas, each designed to build on or Chancellor for Research, Larry H. Danziger. consolidate the gains we’ve made over the last few years:

Mission • Host intellectual property seminars and events for OTM works to ensure that UIC maintains its reputation as faculty and graduate students. a world class research institution with an outstanding faculty. • Attend tradeshows and conferences, We rely on our staff, external contacts, and legal, business, acquiring qualified contacts at each. and financial expertise to support inventors and help partner • Implement feedback mechanisms for faculty and companies develop UIC technologies. licensees; address survey feedback as appropriate. • Update information systems and other processes, Two of our most critical missions are supporting and including an update of the office website and installing encouraging UIC inventors and helping commercial firms a new content management system. license UIC technologies.

Fiscal 2007 Snapshot Disclosures 117 U.S. Patents Filed 162 U.S. Patents Issued 10 Licenses and Options 12 Licenses to Start-up companies 1 Royalties $4,052,586 Patent Expense Reimbursement $291,324

2 2007 Fiscal Year Annual Report From The Interim Director, David Gulley

In 2007, the UIC OTM had a very productive and successful year.

Our first FDA approved drug went to market—PrezistaTM, a new protease inhibitor for drug- resistant strains of HIV. This was the result of research collaborations in the 1990s among several groups, including UIC’s Arun Ghosh (now at Purdue University). You can read more on page 9.

Our 2007 customer satisfaction survey reported the satisfaction level of our licensees and inventors. Eighty-seven percent (87%) of our licensees responding to the survey reported their interactions with the OTM were either satisfactory or very satisfactory, while about 88% of UIC inventors felt the OTM had met or exceeded their expectations.

Other accomplishments for 2007 included improvements to our licensing and other agreements; the introduction of a new start-up license template; educational seminars for faculty and others; focused business partnering at industry events; preparing for the OTM’s move into new space; and a successful collaboration with the College of Business to enable teams of MBA students to develop business plans that won regional and national competitions. For 2008 our plans include completing the relocation of the OTM; increasing our level of engagement and targeting of potential licensees; continuing our patent enforcement and license compliance efforts; expanding our educational programs for faculty and staff; enhancing our relationship with the College of Business Administration; and increasing our collaboration with UIUC’s OTM to support scaled- up web-based marketing and communications.

Since April 2007, it has been my pleasure to work with such a dedicated and enthusiastic team of professionals at the OTM. I thank them for their commitment to making a difference and posi- tively impacting people’s lives.

We look forward to a successful 2008 and I welcome your feedback on how we can improve our service to you and the campus.

David L. Gulley, Ph.D. Interim Director and Associate Vice President for Technology and Economic Development

3 2007 Fiscal Year Annual Report About the Office of Technology Management

The Office of Technology Management (OTM) currently has 14 full-time equivalent employees, 6 part-time student interns, and numerous outside business and legal consultants at its disposal.

The office has adopted a documented, systematic and timely process for the analysis, protection, and commercialization of university intellectual property. In addition, the OTM has developed ongoing productive relationships with faculty, staff and industry.

Due to the foresight, efforts and support from campus, University leadership, and the University’s Board of Trustees, the OTM is surrounded by a more vibrant entrepreneurial environment than ever before. This environment facilitates technology transfer activities, the formation of start-up companies, and ultimately local and state economic development.

The OTM Process

U.S. Patenting / U.S., Foreign Patenting

Licensing

Research Summaries Screening Assessment Marketing License Compliance Disclosed Evaluation Negotiations

DISCLOSURES OF RESEARCH SUMMARIES The OTM actively reaches out to faculty to encourage invention disclosures, called “research summaries” of potentially commer- cializable intellectual property.

LICENSING ● Screening Evaluation ● Marketing Within six to eight weeks of receiving a disclosure, a screening Considerable time and resources are devoted to researching team presents a business-case analysis, called a screening and contacting the best possible licensing partners. evaluation, to the office with a recommended course of action ● License Negotiations regarding commercialization. The results of the screening The OTM conducts license negotiations with interested industry evaluation are then presented to the inventors. partners, taking care to formulate the best possible agreements. ● Assessment ● Compliance When warranted, a more thorough business analysis is After a technology is licensed, the OTM continues to monitor completed which may involve the services of outside consultants the licensee to ensure all terms and conditions are adhered to, to connect with industry experts. This adds to the OTM’s and the technology is successfully taken to market. understanding of the potential market for the technology and 4 helps determine further patenting and marketing actions. 2007 Fiscal Year Annual Report Invention Disclosures

The Office of Technology Management provides a variety of Fiscal 2007 Disclosures by College/Unit educational and informative events for the campus community. Applied Health Sciences 2 Liberal Arts and Sciences 14 In fiscal2007 we focused on department specific events and Dentistry 1 Medicine 61 one-on-one meetings with faculty across campus. We also Education 1 Nursing 1 hosted an inventor recognition gathering co-sponsored by Engineering 20 Pharmacy 14 the Colleges of Business, Pharmacy, and Medicine. Fiscal 2007 Disclosures by Type Campus Invention Disclosures: The types of disclosure are determined by OTM and used on Fiscal 2003-Fiscal 2007 our website and flyers to facilitate industry identification of During the fiscal year, ending June 30, 2007, 117 inventions technologies of interest. were disclosed by the Chicago campus. • Anitbodies 1 • Health Information 3 • Cardiovascular 6 • Immunology 3 150 • CNS 5 • Infectious Disease 4 • Communications 2 • Inflammation 3 120 122 • Data Organization 12 • Materials 3 117 • Dental 2 • Miscellaneous 24 90 • Diagnostic 4 • Oncology 8 87 83 84 • Drug Delivery 10 • Opthamology 2 60 • Engineering 12 • Proteomics 1

s • Graphics, Visualization 2 • Research Tools 2

30 • Hardware 1 • Stem Cells 4 • Health Imaging 4 FY03 FY04 FY05 FY06 FY07 Disclosure

Licensing Activity Licenses and Options: Fiscal 2003-Fiscal 2007 Number of Start-Ups: Fiscal 2003-Fiscal 2007

33 30 8 28 25 7

5 5 5 15 4 14 12 3 2 5 1 1 1 1

FY03 FY04 FY05 FY06 FY07 FY03FY03 FY04FY04 FY05FY05 FY06FY06 FYFY07

Fiscal 2007 Licenses and Start-up Companies Licensed in Fiscal 2007 Options by College/Unit OrthoAccel Technologies, Inc. Dentistry 4 OrthoAccell Technologies designs, develops, markets, Engineering 1 and sells a revolutionary orthodontic device which reduces Liberal Arts and Sciences 2 the treatment time for braces by half. Medicine 4 Public Health 1 5 2007 Fiscal Year Annual Report Patent Activity

A patent is a property right granted by the U.S. Government Provisional applications can be filed without claims, inventor- or other foreign government that allows inventors (and patent ship determinations or formal papers. They merely “hold the owners) to receive value for their intellectual innovations by date of filing” however, and will not result in a patent issued by providing the patent holder with a time-limited (20 years in the the U.S. Patent and Trademark Office. They must be followed U.S.) exclusive monopoly. In exchange, the patent describing up with a regular (non-provisional) U.S. patent filing within a the new innovation is published, thereby advancing general year’s time in order to obtain patent protection. knowledge and contributing to growth in that field. Patent property rights are like other property, and can be In the U.S., patent applications can be of two general types: sold, leased or transferred to others for “royalties,” most often provisional or non-provisional (“regular” applications). Provisional through licensing. applications are often used to file quickly when necessary to preserve the right to file US or foreign applications at a later time.

Fiscal 2007 Patent Activity Fiscal 2007 U.S. Patent by College/Unit Filed Issued U.S. Applications Filed 162 Applied Health Sciences 1 0 U.S. Patents Issued 10 Business Affairs 1 0 Dentistry 8 0 Engineering 27 1 Liberal Arts and Sciences 17 3 Medicine 91 5 Pharmacy 17 1

Patent Reform 2007 Recent court decisions by the Supreme Court and proposed changes to the patent law may impact our ability to both get patents and to enforce patents.

Those who have actually invested in protecting intellectual property (IP) will eventually have to pay even more to protect the IP from those who choose to use it without appropriate permission or recompense. This may favor large corporations in some business areas but will also have a strong negative impact on the role of universities in economic development, and technology commercialization and on start-up companies, and small businesses seeking venture capital and other investments.

In September 2007, the House of Representatives passed elements of statute H.R.1908 and S1145; the legislative reform still has some way to go before becoming law. We will be carefully analyzing how this will impact the commercialization activity of the University.

6 2007 Fiscal Year Annual Report Fiscal 2007 Issued U.S. Patents

Patent No. Inventors Title Department 7,084,105 Ananda Chakrabarty, Tapas Das Cytoxic Factors For Modulating Microbiology and Immunology, Gupta, Olga Zaborina, Vasu Punj Cell Death Surgical Oncology, General Surgery

7,091,195 John Pezzuto, Jerome Kosmeder II, Method of Preparing and Use Medicinal Chemistry Ze-Oi Xu, Nian Zhou, of Prodrugs of Betulinic Acid and Pharmacognosy Miriam Goldsmith

7,109,235 Arun Ghosh Microtubule Stabilizing Compounds Department of Chemistry

7,118,876 Angela Tyner, Jason Derry Altered Intracellular Localization Molecular Genetics of BRK/Sik Protein Tyrosine Kinase In Humane Prostate Tumors

7,118,858 Mark Rasenick, Robert Donati, Marker for Antidepressant Therapy Physiology and Biophysics, Sadamu Toki and Methods Related Thereto Psychiatry

7,157,489 Arun Ghosh, Geoffrey Bilcer, HIV Protease Inhibitors Department of Chemistry Thippeswamy Devasamudram

7,160,898 Miodrag Radulovacki, David Carley Pharmacological Treatment Pharmacology, Respiratory for Sleep Apnea and Critical Care

7,179,508 Luke Hanley, Sanja Tepavcevic, Improved Conducting Polymer Films Department of Chemistry Yongsoo Choi and Method of Manufacturing the Same by Surface Polymerization Using Ion Assisted Deposition

7,191,110 Noam Alperin, Lewis Sadler, Francis Patient Specific Circulation Model MRI Facility, Mechanical Loth, Meide Zhao, M. Clark, Engineering, Neurosurgery Fady Charbel

7,208,928 Dragan Nebrigic, Milan Jevtitch, Oscillatorless DC-DC Power Converter Electrical and Vladimir Gartstein, William Milam, Computer Engineering Nicholas Busko, James Sherrill, Thomas Milam

7 2007 Fiscal Year Annual Report Income Distribution

Income distribution in any given year does not correlate exactly to the income received for that year. There is a lag time between receipt of income and the actual distribution. Income available for distribution equals royalties and revenue minus all expenses attributable to IP commercialization, including patent expenses. It is possible for the income available for distribution in a fiscal year to be higher than the royalties and revenue for that year, because it may also include undistributed income from prior years.

Income Distribution: Fiscal 2006-Fiscal 2007 Fiscal 2006 Fiscal 2007 [1] Since 2005, 5 percent of the income received from [1] Pre-litigation withhold $157,542 $153,680 a license is placed into a litigation fund [2] Other share $8,906 $8,438 [2] Other share primarily results from another institution’s [3] Inventor share $308,361 $331,045 share from a jointly owned invention. [4] University share $1,011,525 $763,159 [3] If there is more than one inventor, the 40 percent [5] Distributed to $1,414,544 $1,203,465 of revenue is shared among all inventors. inventors college [4] The university share goes to the Office of the Provost. [6] Year-end balance of $30,243 $153,368 [5] The unit distribution goes to the inventor’s college. undistributed income In cases involving multiple colleges and inventors, the proceeds are shared between them with a split they determine. [6] Undistributed income results when there is no proceeds distribution agreement in place or agreement cannot be reached among inventors and colleges; the money is held in this account until agreement is achieved.

1.0 0.8 0.6 0.4 0.2 0.0 Income and Expenses

Royalties: Fiscal 2003-Fiscal 2007 Patent Expense Reimbursement: (in millions of dollars) Fiscal 2003-Fiscal 2007 Royalties are defined as payments under option and (in thousands of dollars) license agreements. The Office of Technology Management receives reimbursement for patenting expenses through licensing agreements where 5 patent reimbursement is included in the business terms.

4 4.05 3.78 800 3 3.07 700 2.92 2.53 600 2 500

1 400 602,865

FY03 FY04 FY05 FY06 FY07 300

4 4

200 32 1,

100 29 268,72 248,85 FY04 FY05 FY06 FY07

8 2007 Fiscal Year Annual Report FDA-Approved Drug

Hope Renewed: A new therapy for patients with drug resistant HIV There is hope once again for patients infected with drug resistant strains of the Human Immunod- eficiency Virus (HIV). PrezistaTM, a new protease inhibitor with the ability to stunt drug-resistant strains of HIV, received FDA approval in the summer of 2006. The development of this structurally unique compound first known as TMC-114 resulted from a collaboration of several groups, including the University of Illinois at Chicago (UIC) in the lab of Dr. Arun Ghosh (now at Purdue University).

The chemical structure of PrezistaTM allows it to interact with a region of the protease that does not mutate and remains consistent in various strains of the virus. This is a particular advantage as the virus rapidly mutates and “outsmarts” other drugs within the first few months of treatment. PrezistaTM presents a new option and gives hope to more than 40% of HIV patients that have drug-resistant strains.

The new drug received rapid approval from the FDA based on a 24-month clinical study that demonstrated that 70% of the patients responded to treatment. PrezistaTM is administered in combination with a small dose of Ritonavir and other anti-HIV drugs. Ritonavir, a protease inhibitor that has been in use for several years, slows the degradation of PrezistaTM thereby raising the potency of the drug and increasing its efficacy. PrezistaTM is currently marketed and sold by Tibotec, Inc., a division of Ortho Biotech Products, L.P.

More than one million people are currently living with HIV within the US and more than half a million Americans have already died after developing AIDS, according to the Center for Disease Control (CDC). The World Health Organization (WHO) estimates that over 40 million individuals are infected with HIV worldwide. While this new drug is not a cure, it has provided renewed hope for current therapies for drug resistant strains of HIV and AIDS. Dr. Ghosh continues research to improve upon the original drug design to develop even more effective compounds to target the deadly virus.

9 2007 Fiscal Year Annual Report Technologies

The University of Illinois at Chicago boasts an astounding depth and breadth of research, as represented by this sampling of some of the technologies our office receives in the form of research summaries and is actively marketing.

Research Tools Seed Engineering A Screen for Molecules that Inhibit Formations of A-Beta Oligomers Phenylalanine to Prevent Damage from the Harmful and Lethal Effects of UV and Possibly The present UIC invention is directed towards a yeast Other Stresses in Seedlings high-throughput screen for detecting compounds that inhibit Through experimentation, inventors have been able to prove amyloid-beta aggregation. It also provides a yeast in vivo assay that when phenylalanine ( an essential amino acid present for amyloid-beta aggregation. The assay involves replacing the naturally in plants) is introduced in etiolated seedlings, it can N-terminus of the translational release factor, Sup35, with be used by the phenylpropanoid pathway ( the biochemical Abeta-42mer, and examining the activity of said construct in reactions starting with prephenates and ending with many an ade1-14 yeast strain in which the normal Sup35 gene was essential compunds like cinnamaldehydes, flavonoids etc) to deleted, and inhibition of release factor translation termination produce a range of UV absorbing compounds which mitigate activity of the fusion construct can be assayed for growth the harmful effects of UV rays on plants. on –Ade medium. Benefits Benefits • Protection to plants from UV damage • Easily detects compounds that inhibit amyloid-beta oligomer • Increased ratio of seedling survival vs. mortality formation but do not inhibit protective fiber growth • Prevention from UV-induced seedling death • Selects compounds with more “drug-like” properties • Better and stronger crops (e.g., membrane permeability and cytotoxicity effects) Areas of Application compared to biochemical HTS screens • Crop plants • Clean read-out against a null background in a heterologous, • Seed engineering yet eukaryotic environment, compared to mammalian cells • Plant UV damage protection • Self-renewal system • Simple handling • Fast discrimination of real hits from false positives • Inexpensive culture conditions Areas of Application Transplant Rejection • Screening for compounds that inhibit beta plaque formation Tolerogenic Biodegradable Artificial Antigen Presenting System For the Treatment of Autoimmune Disease and Transplant Rejection The UIC inventor has designed a biodegradable micro-sphere based artificial antigen presenting system to induce toler- ance or to activate immune response. The technology will be applicable in numerous immunological diseases, as well as in preventing transplant rejections. Benefits • Applicable to multiple immunological diseases • Flexibility and ease of modification to obtain desired effect for specific immune mediated diseases • Reliable technique that is resistant to changes in vivo and creating undesirable effects Areas of Application • Autoimmune diseases: diabetes, rheumatoid arthritis, autoimmune thyroid disease, myasthenia gravis 10 • Transplant rejection 2007 Fiscal Year Annual Report Therapeutics A Cell Penetrating ARF Peptide Inhibitor Characterization of Human Embryonic Stem of the FoxM1 Transcription Factor is an Cell-Like Cell from Umbilical Cord Blood and Effective Treatment for Hepatocellular Immune Regulation of Human Umbilical Cord Carcinoma (HCC) in vivo Blood-Derived New Stem Cells on T Lymphocytes The present invention is directed towards a method of UIC researchers have discovered a method to identify and iso- treatment of HCC using parenteral dosage form of the ARF late a new embryonic stem cell-like cell from human umbilical peptide. The present inventors have demonstrated that the cord blood named cord blood embryonic stem cell (CB-ES). Like ARF peptide can effectively penetrate cancerous cells, and ES cells, CB-ES posses ES markers including high potential of do not possess the usual problems of rapid in vivo degrada- self-renewal and expressing ES molecular markers OCT-4, Nanog, tion associated with conventional peptide therapeutics. The SSEA-3, SSEA-4, along with hematopoietic stem cell markers CD9, inventors showed that mice having HCC when subjected CD45, and CD117. The scientists also discovered that when to daily injections of a previously synthesized ARF certain CB-ES cells are injected into the peritoneal cavity of diabetic peptide sequence for 4-8 week periods, significantly showed mice, they migrate into the pancreas and differentiate into a decrease of the proliferation and size of liver tumors. This insulin-producing cells. Moreover, CB-ES cells act as immune peptide sequence is an inhibitor of the forkhead box m1b modulators and can radically stop the auto-immune destruction (Foxm1b) transcription factor, and causes selective apoptosis caused by immune cells, thus allowing the stem cell-derived of hepatic tumor cells and inhibits angiogenesis of the HCC insulin-producing cells to replace the damaged islet beta cells region. The inventors also demonstrated that the technique in type I diabetes. induces apoptosis of human hepatoma cells correlated with Benefits diminished expression of the anti-apoptotic proteins surviving, • A new type of stem cell that expresses embryonic markers PLK1 and aurora B kinase. The present invention thus effec- • High potential for expansion; high pluripotency tively demonstrates a method for selective hepatic delivery of • Easy to isolate and culture from cord blood the ARF peptide in vivo to limit hepatic tumor progression and • Low immunogenicity and unique function of immune regulation selectively induce apoptosis of HCC cells. Areas of Application Benefits • Treatment of diabetes • Selective elimination of FoxM1B only in tumor cells and not • Regenerative medicine in normal cells • Stem cell therapies • Targeted cancer therapy • Scientific research • Diminished side effects caused by preventing proliferation of the rapidly growing cells of the intestinal mucosa, immune system, hair and skin • No risk of extensive in vivo degradation associated with conventional peptide therapeutics Areas of Application • Hepatocellular carcinoma – liver cancer • Tumor suppression

11 2007 Fiscal Year Annual Report Method of Cancer Therapy by Selective Prostanoid for Treatments of Medical Disorders Knock-Down of IG20 Splice Variants Recognizing the need for a novel treatment of sleep apnea, The researchers have determined the specific IG20-splice the inventors at UIC have developed a specific method for variant required for cancer cell survival and provide a method the prevention or amelioration of sleep-breathing disorders. of cancer therapy by selectively knocking down the gene Through an effective amount of antagonists of prostanoids responsible for expressing that particular splice variant using that interfere with the activity of endogenous prostanoids gene silencing techniques. The researchers have demonstrated or a combination of prostanoid antagonists and other tested that down-modulation of said specificIG20 -splice variant pharmacological agents, this technology has been able to causes spontaneous apoptosis in majority of the cancer cells, improve both central and obstructive sleep-related breathing and the small minority of cancer cells which do not undergo disorders. By interfering with apnea-genic sensory inputs to the spontaneous apoptosis, become more susceptible to brainstem, the present invention will have applications to conventional cancer therapy using chemotherapy, TNF, TRAIL, a variety of sleep-related breathing disorders. or gamma radiation.The present invention also provides Benefits sequences of siRNA (small interfering RNA) that can differentially • Alleviation of sleep-related breathing disorders down-regulate IG20 splice variant expression with differential Areas of Application effects on spontaneous apoptosis. • Sleep apnea syndrome Benefits • Upper airway resistance syndrome •Anti-sense knock-down of the specific IG20-splice variant • Apnea of prematurity is very selective due to effective molecular recognition and • Cheyne-Stokes respiration leads to spontaneous apoptosis of only cancer cells and • Obesity hypoventilation syndrome not normal cells • Snoring • Cancer cells which do not undergo spontaneous apoptosis become more susceptible to conventional cancer therapy • Elimination of cancer cells by the present anti-sense therapy can circumvent the problem of non-selective toxicity to normal proliferating cells • Can be used at a very early stage in malignant cancer Areas of Application • All forms of malignant cancer therapy

12 2007 Fiscal Year Annual Report Virtual Reality Role of IG20 Splice Variants in Cell Dynallax: A novel barrier strip autostereoscopic Growth and Death (AS) display using a solid-state dynamic TRAIL, (also called Apo2L) belongs to the tumor necrosis factor parallax barrier to create 3D vision family, activates rapid apoptosis in tumor cells, and binds to Dynallax is head-tracked, directing view channels to positions the death-signaling receptor DR4. in space reported by a tracking system in real time. Such This invention proposes a new sensitivity to cell growth and head-tracked parallax barrier systems have traditionally death; it defines a pro-apoptotic protein that can effectively supported only a single viewer, but by varying the barrier period interact with TRAIL death receptors. The novel technique also to eliminate conflicts between viewers, Dynallax presents four significantly enhancesTRAIL induced apoptosis by facilitating independent eye channels when two viewers are present. DISC formation. Each viewer receives an independent pair of left and right Benefits eye perspective views based on their position in 3D space. • Enhancement of cell-proliferation and cell death The display device is constructed using a dual-stacked LCD • Susceptible to chemotherapy and radiation therapy monitor where a dynamic barrier is rendered on the front pertaining to cancer treatment display and the rear display produces a modulated VR scene • Non toxic approach composed of two or four channels. Specifically, the benefits of Areas of Application Dynallax are: expanded view distance working range, reduced • Chemotherapy sensitivity to system latency during head movement, eliminated • Radiation Therapy physical barrier registration, ability to disable the barrier and convert the display to 2D, and the affordance of two indepen- dently tracked viewers, each with their own AS perspective of the virtual world. Benefits • No restrictions on head movement speed • No headgear or goggles needed • Easy conversion from 2D to 3D Areas of Application • Scientific visualization (laparoscopic surgery for instance), arts and visual media, gaming and video and eventually TV

13 2007 Fiscal Year Annual Report Contacts

David Gulley, Interim Director Connie M. Cleary, Associate Director e: [email protected] • p: 312 996 0722 e: [email protected] • p: 312 996 0447

Technology Managers Business and Finance Adam Falconer, Technology Manager Melissa Miner, Assistant Vice President, Technology e: [email protected] • p: 312.996.3226 & Economic Development e: [email protected] • p: 217-265-5446 Colin James, Technology Manager e: [email protected] • p: 312.996.7779 Colleen Glascott, Project Coordinator e: [email protected] • p: 312.413.1200 Shrijay Vijayan, Technology Manager e: [email protected] • p: 312.996.4129 Nichole Lynch, Project Coordinator e: [email protected] • p: 217.265.5455 Sean Kim, Associate Technology Manager e: [email protected] • p: 312.413.9691 Michael Isaac, Project Specialist e: [email protected] • 312.996.7018 Shayan Sartipi, Associate Technology Manager e: [email protected] • p: 312.996.1595 Patents Jeff Norgle, Patent Coordinator Information Technology e: [email protected] • p: 312.413.9736 Mike Bohlmann, Senior Manager of Information Systems Claudia Gatch Manaila, Project Specialist e: [email protected] • p: 217-333-3781 e: [email protected] • p: 312.996.0024

Alex Esparza, IT Technical Associate Business Analyst e: [email protected] • p: 312.413.8454 Justyna Ciegotura, Analyst e: [email protected] • p: 312.996.2602

Office of Technology Management University of Illinois at Chicago (MC 682) 1853 West Polk Street, Suite 446 • Chicago, Illinois 60612 p: 312.996.7018 • f: 312.996.1995 • e: [email protected]

14 2007 Fiscal Year Annual Report UIC